There will be a center for testing the quality of cells and stem cells according to international standards.

The ceremony was attended by Dr. Nguyen Ngo Quang - Director of the Department of Science, Technology and Training (Ministry of Health); Dr. Hoang Hoa Son - Deputy Head of the Department of Science and Technology Management, Department of Science, Technology and Training (Ministry of Health); Associate Professor - Dr. Pham Van Phuc, Director of the Stem Cell Institute, University of Science, VNU-HCM; Professor Kawamata Shin, CEO of Cyto-Facto Inc; Ms. Tran Thi Lam, Founding Chairwoman of Hoa Lam Group, Chairwoman of the Board of Directors of Hoa Lam Shangri-La Healthcare; Dr. Truong Vinh Long, Deputy Head of the Strategic Committee of Hoa Lam Shangri-La High-Tech Healthcare Park...

Scene of the signing ceremony

With the signing of the memorandum of understanding, Hoa Lam Shangri-La and Cyto-Facto will work together in the development of cell, stem cell and gene therapies.

Specifically, Cyto-Facto will provide training, consulting and technology transfer in cell and stem cell production (including mesenchymal stem cell production from knee synovial membrane) according to Japanese quality control standards; at the same time, provide consulting support in implementing an automated cell and stem cell processing system for Hoa Lam Shangri-La Healthcare. Cyto-Facto will also advise on the establishment of a Cell and Stem Cell Quality Control Center according to international quality standards for Hoa Lam Shangri-La Healthcare.

The cooperation between Hoa Lam Shangri-La Healthcare and Cyto-Facto Inc is expected to continue to promote the development of Hoa Lam Shangri-La High-Tech Healthcare Park, especially in the fields of stem cells and regenerative medicine.

Signing of cooperation agreement between Hoa Lam Shangri-La Healthcare and Cyto-Facto

Currently, stem cells are widely used in regenerative medicine, regenerative medicine as well as disease treatment. International cooperation to produce research and deploy stem cell applications will bring the opportunity for a healthier life to many people with chronic and serious diseases.

Cyto-Facto (Kobe, Japan) is the first company to be spun off from the Kobe Foundation for Biomedical Research and Innovation (FBRI), a core organization of the Kobe Biomedical Innovation Cluster (KBIC), the largest life science-biomedical cluster in Japan. Cyto-Facto has accumulated experience in manufacturing technology and has deployed production lines for stem cells and immune cells, including CAR-T cells (chimeric antigen receptor T cells), iPS cells, and mesenchymal stem cells (MSCs) at various stages of development. In particular, Cyto-Facto is known as the first Asian company to manufacture commercial CAR-T products under PIC/S GMP.

Source: https://thanhnien.vn/se-co-trung-tam-kiem-chuan-chat-luong-te-bao-va-te-bao-goc-theo-chuan-quoc-te-185241217185634242.htm